Publications by authors named "Antonella Falletta"
Article Synopsis
- Immunotherapy shows potential benefits even for patients with advanced cancer, particularly using treatments like cyclophosphamide, IL-2, and radiation.
- A study analyzed immune changes in 23 end-stage cancer patients over time, tracking 16 cytokines to see their relationship with overall survival and disease progression.
- Results indicated that higher levels of IL-2 and specific cytokine combinations at baseline might predict better outcomes, suggesting that monitoring cytokine profiles could help guide treatment decisions.
Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study.
ESMO Open
October 2020
Background: Anticancer drugs can interact with the tumour microenvironment and their effects could be exploited to favour anticancer immune response. Eribulin contributes to tumour vasculature remodelling and transforming growth factor β (TGF-β) modulation in experimental models and in humans. We performed a prospective, translational, exploratory analysis of the levels of circulating cytokines at different time points in patients with metastatic breast cancer treated with eribulin.
View Article and Find Full Text PDFBackground: Regorafenib is an oral small-molecule multikinase inhibitor approved in third or later line of treatment for patients with metastatic colorectal cancer (mCRC). Regorafenib has shown significant benefits in overall survival and progression free survival in two phase III trials compared to placebo in patients with mCRC who had progressed on previous therapy.
Aim: To identify an immune profile that might specifically correlate with the outcome in patients treated with regorafenib.